Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 4/20 | 0.65 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 5/20 | 0.35 |
| ▸ | HTR2A | P28223 | 4/20 | 0.35 |
| ▸ | HTR2B | P41595 | 3/20 | 0.35 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | FADS1 | O60427 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7695900 | 0.89 | KCNA3 (0.68) | KCNA3CYP2A6KCNA5MAOBMAOA | |
| SCHEMBL3797704 | 0.83 | KCNA3 (0.65) | KCNA3CYP2A6KCNA5HTR2CHTR2A | |
| SCHEMBL3794876 | 0.81 | KCNA3 (0.68) | KCNA3CYP2A6KCNA5HTR2CHTR2A | |
| SCHEMBL11498084 | 0.80 | KCNA3 (0.70) | KCNA3CYP2A6KCNA5HTR2CHTR2A | |
| SCHEMBL10921659 | 0.79 | KCNA3 (0.60) | KCNA3CYP2A6KCNA5MAOBMAOA | |
| SCHEMBL827370 | 0.79 | KCNA3 (0.59) | KCNA3CYP2A6MAOBMAOAHTR2C | |
| SCHEMBL10918965 | 0.76 | KCNA3 (0.65) | KCNA3CYP2A6KCNA5MAOB | |
| SCHEMBL29679112 | 0.76 | KCNA3 (0.56) | KCNA3CYP2A6KCNA5MAOBMAOA | |
| SCHEMBL28792214 | 0.76 | KCNA3 (0.56) | KCNA3CYP2A6KCNA5MAOBMAOA | |
| SCHEMBL10922826 | 0.75 | KCNA3 (0.68) | KCNA3CYP2A6KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330460-B1 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2007-03-21 | — | — | EP | disclosed |
| US-6939871-B2 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-09-06 | — | — | US | disclosed |
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1330460-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002034754-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | CYP2B6, CBR1, CYP2A6 | KCNA3 557/4885CYP2A6 3/4885KCNA5 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.